| Esmya (ulipristal acetate) / ASKA Pharma, Gedeon Richter, AbbVie, Perrigo Company |
NCT01953679: Efficacy Study of Two Continuous Regimens of Oral Daily 5 mg or 10 mg of Ulipristal Acetate (UPA), Versus a Dose of 5.0mg UPA for 24/4 Days |
|
|
| Completed | 2b | 180 | US | Ulipristal Acetate | Health Decisions, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Focus: Estrogen-free Oral Contraception | 08/15 | 11/15 | | |
NCT00009659: Use of the Synthetic Hormone CDB-2914 in Treating Symptoms of Menopause |
|
|
| Completed | 2 | 58 | US | CDB 2914 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Postmenopause | | 12/01 | | |
NCT00456924: Low Dose Continuous Administration of the Progesterone Receptor Modulator VA2914 |
|
|
| Completed | 2 | 48 | Europe | VA2914 | HRA Pharma | Contraception, Gynecologic Diseases | | 12/04 | | |
NCT00044876: Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist |
|
|
| Completed | 2 | 56 | US | CDB-2914 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Leiomyoma | 06/07 | 10/15 | | |
NCT01107093: Comparison of CDB-2914 Versus Placebo in the Prevention of Follicular Rupture Post-luteinizing Hormone (LH) Surge |
|
|
| Completed | 2 | 35 | RoW | CDB-2914 (ulipristal acetate), Placebo | HRA Pharma | Contraception | 12/08 | 12/08 | | |
NCT00290251: Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914 |
|
|
| Completed | 2 | 72 | US | ulipristal acetate 20 mg, VA2914; CDB-2914, ulipristal acetate 10 mg, VA2914; CDB2914, placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), HRA Pharma | Leiomyoma | 07/09 | 08/10 | | |
NCT00089414: Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives |
|
|
| Terminated | 2 | 5 | US | Ethinyl Estradiol/Drospirenone, Yasmin, Placebo, CDB 2914, Progesterone antagonist | National Institute of Mental Health (NIMH) | Premenstrual Syndrome, PMS, Premenstrual Dysphoric Disorder, PMDD, Depression | 06/10 | 06/10 | | |
NCT00791297: Study to Evaluate the Safety and Efficacy of Two Contraceptive Vaginal Rings Delivering a Daily Dose of 1500 or 2500 μg of CDB-2914 |
|
|
| Completed | 2 | 55 | US, RoW | CDB-2914 | Population Council | Contraception | 09/14 | 09/14 | | |
2013-005494-53: A Study of the Histological Changes within Ectopic Endometrial Tissue, in Subjects with Pelvic Endometriosis- Following Treatment with Ulipristal Acetate, a Selective Progesterone Receptor Modulator (SPRM). |
|
|
| Ongoing | 2 | 20 | Europe | Ulipristal Acetate (Esmya), Tablet, Esmya | Norfolk and Norwich University Hospitals NHS Foundation Trust, PregLem SA | Endometriosis, Endometriosis, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | | | | |
2016-001719-19: Can a selective progesterone receptor modulator be used for treatment of premenstrual dysphoric disorder? Kan en selektiv progesteronreceptor-modulerare användas för behandling av premenstruell dysfori? |
|
|
| Completed | 2 | 100 | Europe | esmya, Tablet, Esmya | Uppsala University, Uppsala University | Premenstrual dysphoric disorder Premenstruell dysfori, Premenstrual dysphoric disorder Premenstruell dysfori, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Completed | 2 | 120 | Europe | Vilaprisan (BAY1002670), Vilaprisan (BAY1002670, Ulipristal | Bayer | Leiomyoma | 10/16 | 10/16 | | |
|
|
| Terminated | 2 | 23 | Europe | EllaOne, 1: Experimental, 2: Experimental, 3: Experimental, EllaOne placebo | University Hospital, Strasbourg, France | CMT1A | 11/17 | 11/17 | | |
| Completed | 2 | 26 | Europe | Ulipristal acetate, ESMYA®, Placebo | Assistance Publique - Hôpitaux de Paris, Gedeon Richter Ltd. | Adenomyosis | 02/18 | 03/20 | | |
| Completed | 2 | 24 | Europe | ulipristal acetate, Esmya | Manchester University NHS Foundation Trust, University of Manchester | Breast Cancer | 03/19 | 01/23 | | |
CCN013B, NCT03296098: Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive |
|
|
| Withdrawn | 2 | 300 | US | Ulipristal acetate | Premier Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Contraception, Healthy Female | 01/22 | 12/22 | | |
NCT05216952: Ulipristal Acetate for Use in Early Pregnancy Loss |
|
|
| Completed | 2 | 3 | US | Ulipristal Acetate Tablets, Ella, Misoprostol Pill, Cytotec | University of North Carolina, Chapel Hill, North Carolina Translational and Clinical Sciences Institute | Missed Abortion, Anembryonic Pregnancy, Non-Viable Pregnancy | 01/23 | 04/23 | | |
NCT02451826: A Study to Evaluate the Effect of a Contraceptive Vaginal Ring Delivering Ulipristal Acetate Combined With a Single or Repeated Levonorgestrel on Inhibition of Ovulation, Endometrial Changes and Bleeding Patterns in Normal Cycling Women |
|
|
| Unknown status | 1/2 | 19 | RoW | Ulipristal acetate | Population Council | Ovulation Inhibition | 11/17 | 12/17 | | |
